To evaluate the diagnostic utility of metabolic parameter changes on 18F-FDG PET/CT for predicting pathological response after neoadjuvant therapy in NSCLC patients.
Key Findings:
ΔSUVmax% achieved an sAUC of 0.96 with sensitivity of 0.87 and specificity of 0.93.
SUVmax yielded an sAUC of 0.95 with sensitivity of 0.80 and specificity of 0.94.
Heterogeneity sources included treatment regimen, cut-off value, sample size, and adenocarcinoma proportion.
Interpretation:
Quantitative metabolic metrics from 18F-FDG PET/CT show high diagnostic performance for assessing pathological response in NSCLC, potentially aiding in personalized treatment strategies.
Limitations:
Limited number and quality of studies available for analysis.
Need for confirmation through high-quality research.
Conclusion:
Quantitative metrics from 18F-FDG PET/CT may serve as noninvasive tools for response assessment in NSCLC, supporting individualized neoadjuvant strategies.
